相似文献
1
Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?
BJU Int. 2008 Jun;101(11):1335-6. doi: 10.1111/j.1464-410X.2008.07707.x.
2
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.
Drugs. 2011 Feb 12;71(3):255-61. doi: 10.2165/11588930-000000000-00000.
3
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.
Curr Urol Rep. 2008 May;9(3):197-202. doi: 10.1007/s11934-008-0035-y.
4
Uncovering the metabolic complications of androgen deprivation therapy in patients with prostate cancer--where do we take it next?
J Urol. 2015 Jun;193(6):1882-3. doi: 10.1016/j.juro.2015.03.070. Epub 2015 Mar 17.
5
Treatment-related diabetes and cardiovascular disease in prostate cancer survivors.
Ann Oncol. 2008 Sep;19 Suppl 7(Suppl 7):vii86-90. doi: 10.1093/annonc/mdn458.
6
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.
7
Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study.
BMC Cancer. 2021 Nov 22;21(1):1259. doi: 10.1186/s12885-021-08941-y.
8
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23.
9
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. doi: 10.1097/MED.0b013e32814db88c.
10
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23. doi: 10.1093/jnci/djs376.
引用本文的文献
1
Comparing aerobic and resistance exercise emphasis during androgen deprivation and radiation therapy for prostate cancer: A randomised feasibility trial.
Support Care Cancer. 2025 Jun 20;33(7):601. doi: 10.1007/s00520-025-09650-z.
2
Impact of health and lifestyle food supplements on periodontal tissues and health.
Periodontol 2000. 2022 Oct;90(1):146-175. doi: 10.1111/prd.12455. Epub 2022 Aug 2.
3
Considerations for Transgender People With Diabetes.
Clin Diabetes. 2021 Oct;39(4):389-396. doi: 10.2337/cd21-0011.
4
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.
Circulation. 2019 Mar 26;139(13):e579-e602. doi: 10.1161/CIR.0000000000000641.
5
Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
BJU Int. 2019 Aug;124(2):221-241. doi: 10.1111/bju.14681. Epub 2019 Feb 5.
6
Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats.
Mar Drugs. 2018 May 24;16(6):182. doi: 10.3390/md16060182.
7
Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies.
Medicine (Baltimore). 2016 Jun;95(24):e3873. doi: 10.1097/MD.0000000000003873.
8
Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies.
Clin Transl Oncol. 2015 Mar;17(3):223-9. doi: 10.1007/s12094-014-1217-3. Epub 2014 Sep 3.
9
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7.
本文引用的文献
1
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.
2
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
Urology. 2008 Feb;71(2):318-22. doi: 10.1016/j.urology.2007.08.035.
3
Diagnosis and classification of diabetes mellitus.
Diabetes Care. 2008 Jan;31 Suppl 1:S55-60. doi: 10.2337/dc08-S055.
4
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Cancer. 2007 Oct 1;110(7):1493-500. doi: 10.1002/cncr.22933.
5
Metabolic syndrome: a solution in search of a problem.
J Clin Endocrinol Metab. 2007 Feb;92(2):396-8. doi: 10.1210/jc.2006-0944.
6
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
J Clin Oncol. 2006 Sep 20;24(27):4448-56. doi: 10.1200/JCO.2006.06.2497.
7
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
J Clin Oncol. 2006 Aug 20;24(24):3979-83. doi: 10.1200/JCO.2006.05.9741.
8
Insulin sensitivity during combined androgen blockade for prostate cancer.
J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8. doi: 10.1210/jc.2005-2507. Epub 2006 Jan 24.
9
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care. 2005 Sep;28(9):2289-304. doi: 10.2337/diacare.28.9.2289.
10
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.
Clin Sci (Lond). 2003 Feb;104(2):195-201. doi: 10.1042/CS20020209.
Zotero 插件